Myocardial injury caused by ischemia, infarction, or chronic cardiac stress often leads to irreversible loss of cardiomyocytes and impaired cardiac performance. Cardistem is designed to address these pathological changes by enhancing tissue repair and improving the cardiac microenvironment.

Therapeutic Rationale

Umbilical cord–derived MSCs possess strong regenerative, anti-inflammatory, and paracrine signaling capabilities that support cardiac tissue recovery and functional remodeling.

• • Modulation of inflammatory pathways within injured myocardial tissue
• • Promotion of angiogenesis to improve blood supply to ischemic regions
• • Reduction of fibrosis and adverse cardiac remodeling
• • Secretion of cardioprotective and tissue-repairing factors

Potential Benefits

Cardistem is being developed to deliver meaningful therapeutic benefits for patients with cardiac dysfunction, including:

• • Improvement in cardiac output and myocardial contractility
• • Reduction in heart failure–associated symptoms
• • Enhanced exercise tolerance and functional capacity
• • Improved long-term cardiac resilience and quality of life

Development Focus

Cardistem is part of RCT’s regenerative cardiology research pipeline. Current development efforts focus on safety evaluation, biological activity, and translational readiness to support future clinical studies in cardiovascular indications.